Annovis Bio shares are trading higher after the company announced the completion of data cleaning for its Phase 2/3 study of Buntanetap in patients with mild to moderate Alzheimer's disease, with Topline efficacy data expected in April.
Portfolio Pulse from Benzinga Newsdesk
Annovis Bio announced the completion of data cleaning for its Phase 2/3 study of Buntanetap in Alzheimer's patients, with topline efficacy data expected in April, causing its shares to trade higher.
March 20, 2024 | 11:40 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Annovis Bio's shares are trading higher following the announcement of the completion of data cleaning for its Phase 2/3 study of Buntanetap in Alzheimer's patients, with topline efficacy data expected soon.
The completion of data cleaning for Annovis Bio's Phase 2/3 study of Buntanetap is a significant milestone, indicating progress towards the final stages of the study. The anticipation of topline efficacy data, expected in April, is likely to generate investor optimism, contributing to a positive short-term impact on the company's stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100